ANMAT (Argentina)

ANMAT (the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) is the Argentine Republic's national regulatory authority responsible for the regulation of human + veterinary medicines + biologicals + vaccines + medical devices + IVDs + cosmetics + food + dietary supplements. ANMAT was established by Presidential Decree 1490/92 of 20 August 1992 as a decentralised body of the Ministry of Health with technical-scientific + economic-financial autarchy + jurisdiction throughout Argentina. Decree 1490/92 consolidated previously fragmented regulatory functions (medicines under the Dirección Nacional de Drogas, Medicamentos y Especialidades Medicinales; food under the Dirección Nacional de Alimentos; medical technology under the Subsecretaría de Salud) into a single autarchic regulator under the Ministry of Health.

ANMAT's organisational structure includes:

• Administrador Nacional — chief executive appointed by Presidential Decree on Ministerial recommendation; serves at the discretion of the Executive.
• Sub-Administraciones Nacionales — Sub-Administrations for Medicines + Food + Medical Technology + Administration + Legal Affairs + Inspections + Information Systems.
• INAME (Instituto Nacional de Medicamentos) — medicines regulatory laboratory + post-market surveillance + GMP inspection + bioequivalence assessment + biological characterisation; WHO-prequalified pharmaceutical quality control laboratory.
• INAL (Instituto Nacional de Alimentos) — food regulatory laboratory + food safety + foodborne illness surveillance + dietary supplement regulation; PAHO Regional Reference Laboratory.
• DTM (Dirección de Tecnología Médica) — medical devices + IVDs + diagnostics + medical-device cosmetics + classification + post-market materiovigilance.
• Dirección de Vigilancia + Farmacovigilancia — pharmacovigilance + materiovigilance + cosmetovigilance + post-market surveillance + Sistema Nacional de Farmacovigilancia.
• Dirección de Asuntos Jurídicos — legal affairs + administrative enforcement + administrative proceedings.
• Dirección de Relaciones Internacionales — international cooperation + WHO/PAHO + PIC/S + Mercosur + ICH liaison.
• Dirección de Administración — finance, ICT, HR + administration.
• Coordinaciones Regionales — regional offices in Córdoba + Rosario + Mendoza + Bahía Blanca + Mar del Plata + Salta + Tucumán + Posadas + ports-of-entry.

ANMAT operates the ANMAT-Federal Programme (Programa ANMAT Federal) coordinating with provincial regulators across Argentina's 23 provinces + the Autonomous City of Buenos Aires. While ANMAT has national jurisdiction over registration + GMP inspection + import/export, provincial regulators retain primary jurisdiction over pharmacy practice + pharmacy premises + retail-pharmaceutical supply + hospital-pharmacy practice. The ANMAT-Federal Programme provides a coordination framework + capacity-building + harmonised inspection practices across federal + provincial levels.

ANMAT is distinct from + complementary to: SENASA (Servicio Nacional de Sanidad y Calidad Agroalimentaria, regulating veterinary medicines + agricultural inputs + animal-origin foods; ANMAT regulates non-animal-origin processed foods + dietary supplements); INPI (Instituto Nacional de la Propiedad Industrial, regulating pharmaceutical patents); INTI (Instituto Nacional de Tecnología Industrial, regulating industrial standards); the Colegios de Farmacéuticos (provincial pharmacy professional bodies); + the Confederación Farmacéutica Argentina (COFA, federal pharmacy professional confederation).

Legal foundations are Law 16,463 of 1964 (Ley de Medicamentos — the foundational Argentine medicines law), Decree 1490/92 establishing ANMAT, Decree 9763/64 (current implementing regulation of Law 16,463), Decree 150/92 + 177/93 (regulating pharmaceutical specialties), Law 18,284 (Código Alimentario Argentino — CAA), the ANMAT Disposition framework (current GMP Disposition 3266/2013 + medical-device Dispositions 2318/02 + 727/13 + 4306/99 + many others), + Mercosur GMC Resolutions implementing Mercosur harmonisation.

ANMAT is a WHO/PAHO Regional Reference Authority for the Americas (one of the few in the region alongside ANVISA + COFEPRIS + Health Canada) + a PIC/S Member since 1 January 2008 + a WHO Listed Authority + an ICH Observer (eligible for full Membership) + an active ICMRA participant + an IMDRF Affiliate Member. ANMAT is one of the two Mercosur Reference Authorities (alongside ANVISA) under the Mercosur GMC pharmaceutical harmonisation framework + co-leads PANDRH (Pan American Network for Drug Regulatory Harmonisation) alongside FDA + Health Canada + ANVISA + COFEPRIS.

Argentine pharmaceutical regulation operates under a layered framework of primary legislation + ANMAT Dispositions:

• Law 16,463 of 1964 — Ley de Medicamentos; foundational Argentine medicines law regulating manufacture, importation, fractionation, prescription, dispensation + commercialisation of medicines.
• Decree 1490/92 of 20 August 1992 — establishing ANMAT as decentralised body of the Ministry of Health with autarchy + national jurisdiction.
• Decree 9763/64 — current implementing regulation of Law 16,463 (as amended by subsequent decrees).
• Decree 150/92 + Decree 177/93 — regulating pharmaceutical specialty registration, manufacture + importation; introducing the Similar Drug + Reference Drug framework.
• Decree 1271/92 — regulating clinical trials + Good Clinical Practice in Argentina.
• Law 25,326 — Personal Data Protection Law (relevant for clinical-trial + pharmacovigilance data protection).
• Law 18,284 — Código Alimentario Argentino (CAA), the foundational Argentine food law administered jointly by ANMAT + INAL + SENASA + provincial regulators.
• Decree 815/99 — National Food Control System framework.
• ANMAT Disposition 5755/96 — original Argentine GMP framework (now substantively superseded).
• ANMAT Disposition 3266/2013 — current revised Argentine GMP framework substantively aligned with PIC/S GMP Guide + EU GMP + ICH Q7 since PIC/S accession in 2008.
• ANMAT Disposition 2819/04 + 5904/96 + 753/2012 — IVD framework.
• ANMAT Disposition 2318/02 + 727/13 + 4306/99 — medical-device framework with Class I-IV classification.
• ANMAT Disposition 6677/2010 — Good Clinical Practice + Clinical Trial Authorisation framework.
• ANMAT Disposition 5358/2012 — current pharmacovigilance framework substantively aligned with ICH E2 + EU GVP.
• ANMAT Disposition 5904/96 + 2825/2011 — current cosmetics framework substantively aligned with Mercosur GMC Cosmetics Resolutions + EU Cosmetics Regulation.
• Mercosur GMC Resolutions — Common Market Group Resolutions implementing Mercosur pharmaceutical + food + cosmetics + medical-device harmonisation; directly applicable in Argentina + Brazil + Uruguay + Paraguay.

INAME (Instituto Nacional de Medicamentos) is ANMAT's medicines regulatory laboratory + post-market surveillance + GMP inspection + bioequivalence assessment + biological characterisation institute. INAME is one of the foundational components of ANMAT's regulatory infrastructure + serves as a WHO-prequalified pharmaceutical quality-control laboratory + a PAHO Regional Reference Laboratory for the Americas.

• WHO Prequalification of Quality Control Laboratories — INAME is WHO-prequalified for pharmaceutical quality control; one of the few WHO-PQ-approved laboratories in Latin America alongside FIOCRUZ-INCQS (Brazil) + ISP (Chile, in pursuit) + INPM (Mexico).
• ISO/IEC 17025 — INAME is ISO/IEC 17025 accredited for pharmaceutical chemical + microbiological + biological testing.
• PAHO Regional Reference Laboratory — INAME serves as a PAHO Regional Reference Laboratory for the Americas + provides quality-control testing services for PAHO Strategic Fund + WHO PQ programmes serving the region.
• ANMAT regulatory laboratory — INAME conducts pre-registration quality testing + post-market surveillance testing + lot-release testing for vaccines + biologicals on behalf of ANMAT; results are direct ANMAT regulatory evidence.
• Biological characterisation — INAME conducts biological characterisation + bioequivalence assessment + biosimilar comparability assessment + cell-banking + bioassay development.
• GMP Inspectorate base — INAME provides scientific + technical support for ANMAT GMP inspections of Argentine + foreign manufacturing facilities; INAME inspectors are PIC/S-trained.
• Counterfeit-medicine forensics — INAME conducts forensic chemical analysis on suspect counterfeit medicines + supports ANMAT + provincial enforcement.
• Reference standards — INAME maintains the Argentine Pharmacopoeia (Farmacopea Argentina) reference standards + contributes to USP + Ph.Eur. + WHO reference-standard development.
• Capacity-building — INAME hosts training programmes for Latin American pharmaceutical analysts + contributes to WHO + PAHO + Mercosur regulatory-strengthening initiatives.

ANMAT medical-device + IVD regulation operates under ANMAT Dispositions 2318/02 + 727/13 + 4306/99 (medical devices) + 2819/04 + 5904/96 + 753/2012 (IVDs) with a Class I-IV risk-based framework substantively aligned with GHTF/IMDRF + EU MDR + Mercosur GMC Resolutions. Foreign manufacturers must appoint an Argentine Authorised Representative (Representante en Argentina).

• Risk-based Classification (Class I / II / III / IV) — substantively aligned with GHTF/IMDRF + EU MDR with Mercosur + Argentine-specific overlay.
• Registration Certificate (Certificado de Inscripción) — issued by ANMAT DTM (Dirección de Tecnología Médica) based on technical-file review + Argentine Authorised Representative designation + Spanish-language labelling.
• Argentine Authorised Representative (Representante en Argentina) — Argentina-resident legal entity required for foreign manufacturers; bears post-market materiovigilance responsibility + ANMAT regulatory interface.
• ISO 13485:2016 — recognised by ANMAT as QMS evidence framework; Argentine-specific overlay required including Argentine quality records + Representante QMS interface.
• Reliance pathways — ANMAT accepts CE Mark + FDA 510(k) + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence under reliance framework; reliance reduces dossier requirements + accelerates review.
• MDSAP — Argentina is not currently an MDSAP Participating Regulator + does not require MDSAP audit reports; however ANMAT accepts MDSAP reports as supporting evidence + leverages MDSAP-audited manufacturer evidence in inspection planning.
• Mercosur Medical Device Harmonisation — Mercosur GMC Resolutions on medical devices provide harmonised classification + technical-file requirements across Argentina + Brazil + Uruguay + Paraguay; ANMAT + ANVISA jointly lead Mercosur SGT 11 medical-device work-stream.
• Post-market Materiovigilance — ANMAT operates medical-device adverse-event reporting through Sistema Nacional de Tecnovigilancia; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• Cosmetic Notification — cosmetics under ANMAT Disposition 5904/96 + 2825/2011 + Mercosur GMC Cosmetics Resolutions require notification + Spanish-language labelling; INCI-aligned ingredient listing + safety substantiation + cosmetovigilance reporting.
• Argentine UDI — ANMAT is progressively implementing UDI requirements substantively aligned with FDA UDI + EU EUDAMED UDI; Argentine-specific overlay applies.
• Importation Registration — ANMAT Importation Registration required in addition to product registration for foreign-manufactured devices entering Argentina.

ANMAT operates the Sistema Nacional de Farmacovigilancia (SNFVG, National Pharmacovigilance System) under Disposition 5358/2012. The SNFVG is one of the most mature Latin American pharmacovigilance systems + integrates federal + provincial + hospital + community-pharmacy + manufacturer reporting.

• Sistema Nacional de Farmacovigilancia (SNFVG) — coordinated federal-provincial pharmacovigilance network with effector centres in major hospitals + provincial Ministries of Health + Marketing Authorisation Holders.
• WHO PIDM Long-standing Member — Argentina is a long-standing WHO Programme for International Drug Monitoring member (since 1994) + contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre (UMC).
• Online ADR Reporting — ANMAT operates online ADR reporting via the SNVS-FV (Sistema Nacional de Vigilancia de la Salud — Farmacovigilancia) platform; available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — ANMAT accepts E2B(R3) format ICSR submissions substantively aligned with ICH E2B(R3); 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2); ANMAT-specific submission timeline.
• Risk Management Plans (RMP) — ANMAT requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• Active surveillance — ANMAT operates targeted active-surveillance programmes including for HIV antiretrovirals + tuberculosis + COVID-19 vaccines + biologicals + sentinel-site hospital surveillance through major referral hospitals across Argentina.
• Tecnovigilancia + Cosmetovigilancia + Reactivovigilancia — ANMAT operates parallel materiovigilance (Tecnovigilancia) for medical devices, cosmetovigilance for cosmetics + reactivovigilance for IVDs; all under coordinated Sistema Nacional de Vigilancia.

• WHO/PAHO Regional Reference Authority — ANMAT is a WHO/PAHO Regional Reference Authority for the Americas alongside ANVISA + COFEPRIS + Health Canada + FDA; designation reflects ANMAT's mature regulatory system + benefits PAHO Member States through reliance pathways.
• WHO Listed Authority — ANMAT is a WHO Listed Authority recognised for medicines + vaccines + biologicals + WHO PQ reliance.
• PIC/S Member Since 1 January 2008 — ANMAT GMP Inspectorate is a full PIC/S Member; PIC/S accession marked a transformational maturation of Argentine GMP practice + opened reliance routes globally.
• ICH Observer — ANMAT is an ICH Observer eligible for full Membership; ICH guidelines extensively implemented in Argentine regulatory practice including ICH Q7 + Q8 + Q9 + Q10 + Q11 + E2A-E + M4.
• ICMRA Member — ANMAT is a full ICMRA (International Coalition of Medicines Regulatory Authorities) Member alongside FDA + EMA + MHRA + Health Canada + TGA + ANVISA + COFEPRIS + PMDA + NMPA + WHO.
• PANDRH Co-Leader — ANMAT co-leads the Pan American Network for Drug Regulatory Harmonisation (PANDRH) alongside FDA + Health Canada + ANVISA + COFEPRIS; PANDRH is the PAHO-coordinated harmonisation framework for the Americas.
• Mercosur Reference Authority — ANMAT is one of the two Mercosur Reference Authorities (alongside ANVISA) under Mercosur GMC pharmaceutical + food + medical-device + cosmetic harmonisation; co-leads SGT 11 (Health).
• WHO PQ Vendor Recognition — INAME is a WHO-prequalified pharmaceutical quality control laboratory + PAHO Regional Reference Laboratory.
• IMDRF Affiliate — ANMAT is an IMDRF Affiliate Member + draws on IMDRF guidance for medical-device regulation.
• Bilateral MoUs — ANMAT holds MoUs with FDA + EMA + MHRA + Health Canada + TGA + PMDA + ANVISA + COFEPRIS + Chilean ISP + Colombian INVIMA + Uruguayan MSP + Paraguayan DNVS + Peruvian DIGEMID + Cuban CECMED + Brazilian state regulators + Spain AEMPS + Israel MOH.
• ICDRA — active International Conference of Drug Regulatory Authorities participant + has hosted ICDRA Regional Conferences in Buenos Aires.
• ALIFAR + Industry Cooperation — ANMAT engages with Asociación Latinoamericana de Industrias Farmacéuticas (ALIFAR) + Cámara Industrial de Laboratorios Farmacéuticos Argentinos (CILFA) + Cámara Argentina de Especialidades Medicinales (CAEME) + provincial industry associations.
• WTO TBT + SPS Committees — ANMAT contributes to Argentina's WTO Technical Barriers to Trade + Sanitary + Phytosanitary Measures notifications + responses.

• Argentine Authorised Representative (Representante en Argentina) not properly designated — application rejected at ANMAT intake or post-approval compliance failure.
• Spanish-language labelling deficiencies — Spanish (Castilian variant) labelling + Spanish PIL (prospecto) required; many applicants provide Mexican Spanish or other Latin American variants without ANMAT-specific terminology + storage-condition Argentine-climate appropriateness.
• GMP Dispositions gaps — applicants assuming EU GMP / PIC/S GMP compliance is automatically sufficient without addressing Argentina-specific ANMAT Disposition 3266/2013 clarifications + ANMAT-specific quality records.
• Argentine climate-zone stability data missing — Argentine Climate Zone II (temperate, the majority of populated areas) but with Climate Zone IVa (subtropical, NEA region) + Climate Zone I (cold, Patagonia) variations; many applicants provide insufficient zonal-specific stability data.
• Reference Drug / Similar Drug framework misunderstood — Decree 150/92 + 177/93 Reference Drug / Similar Drug framework requires correct identification of registered Reference Drug + bioequivalence at ANMAT-recognised centre; missteps trigger rejection.
• Mercosur harmonisation not leveraged — Mercosur GMC Resolutions provide harmonised dossier elements across Argentina + Brazil + Uruguay + Paraguay; ANMAT + ANVISA-led Mercosur Joint Registration substantially underutilised.
• PANDRH reliance not leveraged — PANDRH reliance pathway underutilised by applicants targeting multiple American markets through FDA + Health Canada + ANVISA + COFEPRIS + ANMAT coordination.
• WHO PQ + PAHO Strategic Fund reliance under-utilised — WHO-PQ + PAHO Strategic Fund-listed products eligible for accelerated ANMAT review.
• SENASA jurisdictional split — veterinary medicines + agricultural inputs + animal-origin foods sit with SENASA (Servicio Nacional de Sanidad y Calidad Agroalimentaria), not ANMAT; avoid filing veterinary or animal-origin food applications to ANMAT.
• Provincial pharmacy practice scope — pharmacy practice + pharmacy premises licensing + retail-pharmacy supply sit with provincial Colegios de Farmacéuticos + provincial Ministries of Health, not ANMAT; ANMAT-Federal Programme coordinates but does not directly regulate provincial pharmacy practice.
• Variations strategy not planned — Type IA / IB / II variations procedure substantively similar to EU but with ANMAT-specific timelines + fee structure + Spanish-language requirements.
• Renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration + market withdrawal.
• Clinical trial Disposition 6677/2010 + CONEP REC steps — Argentine clinical trials require ANMAT CTA per Disposition 6677/2010 + provincial CONEP-registered Research Ethics Committee approval + ANMAT-registered investigator; sponsors sometimes overlook provincial REC variations + provincial pharmacy-practice intersections.
• Pharmacovigilance reporting gaps — ANMAT Disposition 5358/2012 + SNFVG requirements substantively similar to ICH E2 + EU GVP but with Argentina-specific format + SNVS-FV submission requirements + Spanish-language ICSR.
• Importation Registration not obtained — ANMAT Importation Registration required in addition to product registration for foreign-manufactured medicines + devices entering Argentina.

V5 Ultimate provides the operational infrastructure Argentine + foreign-supplier sites need for Law 16,463 + Decree 1490/92 + ANMAT GMP Disposition 3266/2013 + ANMAT Medical Devices Dispositions + Mercosur GMC + PANDRH + Sistema Nacional de Farmacovigilancia + INAME readiness.

• ANMAT GMP Disposition 3266/2013 control framework — PIC/S + EU GMP + ICH Q7-aligned controls (clean rooms, aseptic process, environmental monitoring, computerised systems) with ALCOA+ data-integrity + Argentina-specific clarifications + Argentine climate-zone II/IVa/I stability monitoring.
• ANMAT drug-registration packaging — Argentine CTD-aligned dossier structure with Argentina Module 1 specifics + Module 3 stability + Argentine prospecto (PIL) + Spanish (Castilian) labelling + Argentine Authorised Representative declarations + Decree 150/92 + 177/93 Reference Drug / Similar Drug framework.
• Mercosur GMC workflow — Mercosur harmonised dossier packaging for joint registration across Argentina + Brazil + Uruguay + Paraguay; SGT 11 (Health) coordination.
• PANDRH workflow — PANDRH reliance pathway packaging for products assessed by FDA + Health Canada + ANVISA + COFEPRIS Reference Authorities.
• WHO PQ + PAHO Strategic Fund workflow — WHO-PQ + PAHO Strategic Fund reliance packaging with substantially reduced ANMAT review path.
• Argentine Authorised Representative workflow — foreign-manufacturer Representante en Argentina designation + role-management + Argentina-specific post-market surveillance + ANMAT interface.
• Argentine clinical-trial workflow — ANMAT Disposition 6677/2010 GCP + CONEP-registered provincial REC + ANMAT-registered investigator + Argentine SUSAR reporting via SNVS-FV.
• ANMAT Pharmacovigilance + SNFVG integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Spanish-language ICSR + SNFVG effector-centre coordination + SNVS-FV submission + VigiBase upload + Risk Management Plan packaging.
• Tecnovigilancia + Cosmetovigilancia + Reactivovigilancia workflow — parallel materiovigilance + cosmetovigilance + IVD-vigilance packaging under coordinated Sistema Nacional de Vigilancia.
• Medical-device + cosmetic + IVD workflow — ANMAT Dispositions 2318/02 + 727/13 + 4306/99 + 5904/96 + 753/2012 + Mercosur GMC Cosmetics Resolutions dossier packaging + Class I-IV classification + ISO 13485 + Argentine Authorised Representative + post-market Tecnovigilancia.
• ANMAT Variations workflow — Type IA / IB / II classification + ANMAT procedure + Argentine packaging.
• Renewal workflow — 5-year renewal window tracking + ANMAT procedure packaging.
• Mercosur + PANDRH regional bridging — for companies operating across Latin America, V5 surfaces ANMAT + ANVISA + COFEPRIS + Chilean ISP + Colombian INVIMA + Uruguayan MSP + Paraguayan DNVS + Peruvian DIGEMID + Cuban CECMED + Bolivian AGEMED + Ecuadorian ARCSA + Venezuelan INHRR harmonised dossier-element reuse alongside national-specific extensions.